Form 4: ADAR1 Capital Increases Stake in InMed Pharmaceuticals

ADAR1 Capital Management, LLC and Daniel Schneeberger reported the acquisition of 468,551 common shares of InMed Pharmaceuticals Inc. on May 19, 2026.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger acquired a total of 468,551 common shares of InMed Pharmaceuticals Inc. (INM).
• The purchases occurred on May 19, 2026, across three separate transaction blocks.
• The shares were acquired at weighted average prices ranging from $1.499 to $1.5998 per share.
• Following these transactions, the reporting persons beneficially own 800,000 common shares of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as significant open-market buying by a 10% owner typically indicates strong conviction in the company's underlying value.

Positives

• Increased investment from a 10% owner signals confidence in the company's long-term prospects.
• The acquisition of a significant block of shares provides liquidity and demonstrates commitment from a major shareholder.

Negatives

• None identified in this filing.

Risks

• Market volatility affecting the value of the acquired equity.
• Regulatory and operational risks inherent to the pharmaceutical industry.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations or future financial performance.

Industry Context

StockSavvy.ai notes that insider and major shareholder accumulation in small-cap pharmaceutical companies often precedes strategic developments or reflects a belief that the stock is undervalued relative to its clinical pipeline potential.

Comparison to Industry Standards

• The acquisition behavior is consistent with institutional investors increasing positions in biotech firms during periods of market consolidation.

Stakeholder Impact

• Shareholders may view the increased ownership by a major investor as a stabilizing factor for the stock price.

Next Steps

• Continued monitoring of SEC filings for further changes in beneficial ownership.

Key Dates

Keywords

InMed Pharmaceuticals, INM, ADAR1 Capital Management, Insider Trading, Form 4, Equity Acquisition